CD11c expression in circulating T cells from healthy young women.

<p>CD11c⁺ cells were analyzed by flow cytometry in the CD4⁺ CCR7⁺/^- and CD4^- CCR7⁺/^- CD3⁺ T cell subsets. Gating strategy consisted on the following consecutive gates: lymphocytes, singlets, live CD3⁺ T cells, CD4⁺ or CD4^- T cells, CCR7⁺ or CCR7^- and lastly CD11c⁺. Each bar represents the mean ± SD of normal donors (n = 13). Data were analyzed by Kruskall-Wallis test with Bonferroni post-test correction.</p

Adhesion molecules included in the CD11c⁺ T cell fraction after vaginal Chlamydia infection in mice.

<p>The frequency of the different subsets obtained from combining CCR10, CD8α, CD103 and NK1.1 expression is displayed for each group as a pie chart and as a complementary bar graph. Gating strategy was performed as described in <b><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0154253#pone.0154253.g001" target="_blank">Fig 1</a></b> and in Materials and Methods. The frequency of CD11c positive cells in the T cell fraction as the mean ± SD is shown as a white number in the center of the pie chart for each group in blood (top) and genital tract (GT, bottom). Each colored portion of a pie chart indicates the percentage of a specific subset detailed in the bar chart below. The arcs around the pie show the molecule or combination of molecules to which those proportions correspond (see color legend indicating CCR10, CD8α, CD103 and NK1.1). *Indicates p<0.05 by Student’s t test analyses only for values >5% of the total CD11c⁺ T cells in vaginally (VAG)-infected mice seven days after infection (n = 4) compared to control (n = 3) animals.</p

Multivariate analysis^† of the characteristics associated with high-risk HPV infection.

†<p>The model included those variables that were statistically significant in the univariate analysis (p-value<0.05), those with a p-value lower than 0.10, and those that were considered clinicoepidemiologically important.</p>*<p>Adjustment variables introduced in the final model.</p

HR-HPV and provable HR-HPV* types-specific prevalence in HIV-1 positive women.

<p>HR-HPV and provable HR-HPV* types-specific prevalence in HIV-1 positive women.</p